Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05984953 · ClinicalTrials.gov registry record
Rosuvastatin and Evolocumab for Coronary Artery Disease
A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 195
- Enrollment target
NCT05984953 is a clinical trial that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 195 participants.
The verdict
NCT05984953 has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 195 participants
- Enrollment target
Study Summary
The aim of the retrospective study is to characterize the molecular mechanisms responsible for the effect of statins and evolocumab in patients with stable coronary artery disease. The research team will retrieve and review intravascular imaging and gene expression data previously collected in the catheterization laboratory during the following time-period: 8/1/2013-4/14/2015 and 5/4/2021 - 10/28/2022.
Interventions
- DRUG statin
- DRUG evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2013-08-01 |
| Est. Completion | 2022-10-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05984953
The ClinicalTrials.gov registry entry for NCT05984953 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 195 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which statin is the first listed.
NCT05984953 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05984953 about?
NCT05984953 is a clinical study titled "Rosuvastatin and Evolocumab for Coronary Artery Disease". The aim of the retrospective study is to characterize the molecular mechanisms responsible for the effect of statins and evolocumab in patients with stable coronary artery disease. The research team will retrieve and review intravascular imaging and gene expression data previously collected in the c...
What is the current status of trial NCT05984953?
This trial is currently completed. The enrollment target is 195 participants. The study started on 2013-08-01. Estimated completion is 2022-10-28.
What interventions are being tested in trial NCT05984953?
The interventions under investigation include: statin (DRUG), evolocumab (DRUG).
Who is sponsoring clinical trial NCT05984953?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.